Robert F. Kennedy Jr. would create "significantly more volatility" in health markets if he is confirmed as Secretary of Health and Human Services, making navigating policy risks far more challenging, ...

BioNTech SE and Biotheus announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage ...

RESEARCHERS from SINTEF have developed a “simpler” low-cost carbon capture and storage (CCS) system for sequestering ...

Shares of vaccine makers closed lower Thursday amid reports that President-elect Donald Trump was set to nominate vaccine ...

Shares of BioNTech (BNTX) and Novavax (NVAX) closed with losses of 7%, while Moderna's stock (MRNA) shed 6%. Vaxcyte (PCVX) dropped 4%, and Pfizer (PFE) pulled back 3%. The sizeable declines in these ...

BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Voyager Therapeutics (VYGR – Research ...

John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...

(MENAFN) BioNTech signed an agreement to buy Biotheus, which is a Chinese biotechnology firm, for USD800 million to further enhance its treatment of tumors, stated the German medicinal producer ...

BioNTech is investing in a promising space in oncology by acquiring Biotheus’ PD-L1 and VEGF bispecific antibody.

BioNTech SE ( BNTX, Financials) announced plans to acquire Biotheus, a clinical-stage biotechnology company, for $800 million ...

On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...